×
About 128 results

ALLMedicine™ Tardive Dystonia Center

Research & Reviews  44 results

Electroconvulsive Therapy as a Treatment for Tardive Dyskinesia.
https://doi.org/10.4088/PCC.20r02775
The Primary Care Companion for CNS Disorders; Yahya AS, Khawaja S

May 18th, 2021 - To review the published literature over the last 10 years for the use of electroconvulsive therapy (ECT) in tardive dyskinesia (TD), focusing on the efficacy of this treatment. A comprehensive evidence search of the published literature in the las...

Clinical Spectrum of Drug-Induced Movement Disorders: A Study of 97 Patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597587
Tremor and Other Hyperkinetic Movements (New York, N.Y.); Chouksey A, Pandey S

Nov 13th, 2020 - Drug-induced movement disorders (DIMDs) are commonly encountered, but an often-under-reported subgroup of movement disorders. We aimed to highlight the spectrum of DIMDs in patients taking different groups of drugs at our movement disorder center....

Genetic association study detected misalignment in previous whole exome sequence: assoc...
https://doi.org/10.1097/YPG.0000000000000263
Psychiatric Genetics; Kanahara N, Nakata Y et. al.

Sep 18th, 2020 - Tardive dystonia is one of the most serious types of extrapyramidal symptoms that antipsychotics can cause. There is no established treatment to relieve this symptom, and its etiology is unclear. Recently, we identified very rare single-nucleotide...

A preliminary exome sequence in three patients with tardive dystonia.
https://doi.org/10.1097/YPG.0000000000000248
Psychiatric Genetics; Kanahara N, Nakata Y et. al.

Jan 3rd, 2020 - Tardive dystonia is one of the most serious adverse events that can be caused by antipsychotic treatment, but few studies have examined the etiology of tardive dystonia, and no genetic study using a next-generation sequencing technique has been pe...

Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive...
https://doi.org/10.1097/JCP.0000000000001114
Journal of Clinical Psychopharmacology; Lee D, Baek JH et. al.

Nov 7th, 2019 - Given that switching to clozapine is an important treatment option for tardive movement syndrome (TMS), its effect and clinical correlates have not been fully explored yet. This study investigated the improvement of TMS after switching to clozapin...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  4 results

Validation of the Implantation of a New Electrode for the Treatment of Dystonia
https://clinicaltrials.gov/ct2/show/NCT02509338

May 22nd, 2018 - Deep brain stimulation (DBS) is a validated therapy for treating dystonia and other movement disorders. The main therapeutical target used for treating dystonic syndromes is the internal globus pallidum (GPi). Given the morphology and the topograp...

Evaluation of a Teaching Curriculum on Disruptive Behaviour Disorders
https://clinicaltrials.gov/ct2/show/NCT03151187

Jan 31st, 2018 - Background Information Children with disruptive behaviour include those with Attention Deficit Hyperactivity Disorder (ADHD), Oppositional Defiant Disorder (ODD), Conduct Disorder (CD) and Disruptive Mood Dysregulation Disorder (DMDD). Disruptive ...

Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
https://clinicaltrials.gov/ct2/show/NCT00331669

Mar 4th, 2009 - Deep brain stimulation (DBS) has been established as a new reversible, neurosurgical therapeutic option for patients suffering from disabling neurological movement disorders such as essential tremor and Parkinson´s disease. Recently, deep brain st...

Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
https://clinicaltrials.gov/ct2/show/NCT00114595

Jun 24th, 2005 - Background: One of the major limitations of conventional antipsychotics is their high propensity to cause extrapyramidal symptoms (EPS). Tardive dyskinesia (TD) in particular causes problems, insofar as it is common, and resistant to treatment. TD...

see more →

News  2 results

Experimental Tardive Dyskinesia Drug Hits Mark in Phase 3
https://www.medscape.com/viewarticle/852450

Oct 9th, 2015 - NBI-98854, an experimental drug for tardive dyskinesia being developed by Neurocrine Biosciences, led to a statistically significant reduction in symptoms of the movement disorder in a phase 3, placebo-controlled trial called Kinect 3, the company...

Surgical considerations for tremor and dystonia
https://www.mdedge.com/ccjm/article/95792/surgical-considerations-tremor-and-dystonia/page/0/1

Jul 1st, 2012 - Patient selection Appropriate patients for DBS include those with an unequivocal diagnosis of dystonia and significant disability. Etiology and type of dystonia should also be considered.

see more →